ClinConnect ClinConnect Logo
Search / Trial NCT03983473

Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Jun 11, 2019

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

The MICROSPA trial is studying the differences in gut bacteria and other substances in the blood and immune system of patients with Crohn's disease, particularly those who also have a related condition called spondyloarthritis. Researchers want to understand how these factors might be linked to Crohn's disease and spondyloarthritis by comparing three groups: patients with only Crohn's disease, patients with only spondyloarthritis, and those who have both conditions. They will also look at a group of healthy individuals for comparison.

To qualify for this study, participants must be at least 18 years old and fall into one of the three patient groups mentioned. They cannot have had certain medical procedures, like colon surgery, or be on specific medications that could affect the study results. If you decide to participate, you'll provide a stool sample and some blood for testing. This could help researchers identify potential biomarkers, which are indicators that could lead to better understanding and treatment of these conditions in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years.
  • * Patients will be recruited according to 3 groups:
  • Patients with Crohn's disease and axial spondyloarthritis according to the criteria below.
  • Patients with Crohn's disease (MC patients) with a diagnosis established according to clinical, biological criteria, radiological, endoscopic and / or histological studies for 3 months. With diagnosis of exclusion of a spondyloarthritis on criteria ASAS and / or New York modified.
  • Patients with axial spondyloarthritis (SpA patients) with a diagnosis based on modified ASAS and / or New York criteria with exclusion diagnosis of Crohn's disease.
  • Patient with the ability to give free and express informed consent.
  • Exclusion Criteria:
  • History of colonic resection
  • Taking antibiotics or colon preparation for colonoscopy within 8 weeks before stool collection (Temporary contraindication = removal possible before colic or first bowel preparation after the start of colonic preparation).
  • Ostomy at the time of sampling
  • BMI\> 30
  • extreme diet
  • unbalanced diabetes
  • Pregnant woman
  • Patient under guardianship, under curatorship or under the protection of justice Contacts/Locations Central Contact

About Central Hospital, Nancy, France

Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.

Locations

Paris, , France

Nancy, Lorraine, France

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials